02:03 PM EDT, 03/11/2024 (MT Newswires) -- BioNTech (BNTX) said Monday it will present clinical data updates on select investigational cancer vaccines from its pipeline at the annual meeting of the American Association for Cancer Research in San Diego, California, in April.

The company will present longer-term follow-up data on the individualized mRNA-based candidate autogene cevumeran in patients with pancreatic cancer. Also included in the presentation is preliminary phase 1 trial results of the shared tumor-associated-antigen-based mRNA therapeutic cancer vaccine candidate BNT116, in combination with docetaxel, for the treatment of non-small cell lung cancer.

Also to be presented are phase 1/2a trial data for the pretreated advanced or metastatic solid tumors treatment candidate, being jointly developed with Duality Biologics.

The company said it aims to have at least 10 potentially registrational trials in its oncology pipeline by the end of this year.

BioNTech shares climbed nearly 6% in recent trading.

Price: 96.63, Change: +5.36, Percent Change: +5.87